Real-world predictive model for immune checkpoint inhibitor-induced hepatitis using baseline cytotoxic T-lymphocyte counts

Figure 1 Flow chart for patients enrolled in the final study cohorts. IMH: Immune-mediated hepatitis.

Figure 2 Nomogram for predicting immune-mediated hepatitis risk and its receiver operating characteristic curve. A: Nomogram model for predicting immune-mediated hepatitis risk in immune checkpoint inhibitors patients; B: The receiver operating characteristic curve for the nomogram model. ALT: Alanine transaminase; C4: Complement 4; CD: Cluster of differentiation.

Figure 3 Calibration curves of the nomogram in the training and validation cohorts. A: Training cohort; B: Validation cohort.

Figure 4 Decision curve analysis of the nomogram in the training and validation cohorts. A: Training cohort; B: Validation cohort.